Jade Biosciences, Inc. (JBIO)
Healthcare
Biotechnology
19.20 $
-3.0%
vs. previous close
Closing price · As of: 3. Aug 2026
Who owns Jade Biosciences, Inc. (JBIO)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 61.0% of the shares are freely tradable; institutional investors hold 84.8%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
84.8%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
0.9%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
61.0%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
15.3%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
61Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| FMR Inc | 11.64 | 7,085,423 | +2.8 | 03/31/2026 |
| Fairmount Funds Management LLC | 7.48 | 4,553,494 | +0.0 | 03/31/2026 |
| RA Capital Management, LLC | 6.03 | 3,671,083 | +0.0 | 03/31/2026 |
| Bellevue Group AG | 5.75 | 3,501,502 | +4.8 | 03/31/2026 |
| VR Adviser, LLC | 5.29 | 3,220,364 | +0.0 | 03/31/2026 |
| HHG PLC | 5.10 | 3,105,669 | +0.0 | 03/31/2026 |
| Avidity Partners Management LP | 4.60 | 2,801,416 | +100.0 | 03/31/2026 |
| BlackRock Inc | 3.80 | 2,313,949 | -19.4 | 03/31/2026 |
| Vanguard Capital Management, LLC | 2.95 | 1,796,652 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Polar Capital Biotech S Inc | 2.87 | 1,749,308 | +72.3 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.